Search results for: Multi-Indication Medicines
Filter search results
The Many Faces of Innovation
1 June 2012
This report provides a clear explanation of the nature of innovation in medicines. A fully revised and expanded version of the 2005 edition, it updates the literature review of the…
Time Trends in NICE HTA Decisions
1 January 2012
…innovative care and ensure more rapid access to medicines identified as being of… According to the 1999 UK Department of Health consultation document, the fundamental purpose of the National Institute…
Canberra Hypothesis: the Economics of the Prescription Medicine Market
1 July 1975
…prescription medicines. Nevertheless it calls into question the underlying factor – namely the absence or weakness of price competition for pharmaceuticals – on which price controls, such as Britain’s ‘Voluntary…
Alcohol: Reducing the Harm
1 April 1981
…last quarter of a century, the scale of ethyl alcohol consumption can be seen to be enormous if compared to, for instance, that of medically legitimated drugs/medicines. The most frequently…
Pharmaceutical Innovation: Recent Trends, Future Prospects
1 October 1983
…period of ‘therapeutic transition’ in which new medicines have increasingly fallen into this category, that is they have had a greater impact on the quality of life than on beta…
Pharmaceuticals in Developing Countries
1 July 1983
…of medicines. As a contribution to the discussion in this area, OHE is… The Office of Health Economics has recently widened its scope to take a special interest in the…
Patterns of European Diagnoses and Prescribing
1 January 1984
…1982). An important area of international disparity that has received some attention is pharmaceutical consumption. Gisbert (1980) analysed European expenditure data on nine groups of medicines for the 1970s and…
Innovative Chemical Extensions: The Economic Basis of Pharmaceutical Progress
1 December 1988
…disparingly described as ‘me too’ medicines may not be established until several years after they have been available for prescription. It is simply not possible to predict how necessary a…
Economic Evaluation of Growth Hormone Therapy
1 December 1991
…the GP’s clinical freedom to prescribe the medicines that he or she considers necessary for a patient’s treatment’, the families believe that FHSAs may feel that they should exert ‘downward…